PIK3CA and neoplasm: Surprisingly, the recurrence rates of the PIK3CA-mutantation/SHC1-loop+ luminal A tumor patients were lower in the first 5 years after diagnosis than PIK3CA-mutantation/SHC1-loop− luminal A tumor patients (P < 0.01, log-rank test, Figure 5).